title: Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes.
abstract: We report on the use of fludarabine in four patients with splenic lymphoma with villous lymphocytes (SLVL). All four had relapsed after, or failed to respond to, recommended first-line therapies. In each case fludarabine resulted in a complete clinico-haematological response with minimal toxicity, which, in the two patients with long-term follow-up, proved durable. Fludarabine is effective in the treatment of SLVL and should be considered as both a first-line therapeutic option as well as salvage therapy in this condition.
authors.affiliation: Department of Haematology, Royal Bournemouth Hospital.
authors.forename: S
authors.initials: S
authors.lastname: Bolam
authors.forename: J
authors.initials: J
authors.lastname: Orchard
authors.forename: D
authors.initials: D
authors.lastname: Oscier
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D013160:Splenic Neoplasms / Q000188:drug therapy*; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine